Senti Biosciences Raises $53 Million from Amgen and Others in Series A Financing Post author:Sam Post published:February 26, 2018 Post category:BioPharma Senti Biosciences, based in South San Francisco, has completed a $53 million Series A financing. Source: BioSpace You Might Also Like Why Boston-Bound Alexion Could be a Compelling M&A for Larger Drugmakers January 29, 2018 Celgene Partners with Prothena Therapeutics in Potential $2B Deal March 20, 2018 Sarepta Under Pressure As Marathon Pharma Emflaza's Wins FDA Approval for DMD February 9, 2017